Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a69681008a628a443257b49621b2e506 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-397 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-397 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
filingDate |
2018-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd2ca7a43c09e21560b4c080748fe907 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5afdea3e7bd5b0987f2e21c88b078cd |
publicationDate |
2019-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20190141762-A |
titleOfInvention |
Prevention or treatment of tau disease |
abstract |
An object of the present invention is to provide a drug and a method for inhibiting the progression of tau disease such as Alzheimer's dementia. 1- (3- (2- (1-benzothiophen-5-yl) ethoxy) propyl) azetidin-3-ol or a salt thereof has the effect of reducing the amount of phosphorylated tau protein, and also in the brain parenchyma Since it has the effect of reducing the amount of amyloid β protein, it is effective as a prophylactic or therapeutic agent for tau disease. By administering 1- (3- (2- (1-benzothiophen-5-yl) ethoxy) propyl) azetidin-3-ol or a salt thereof, tau disease can be prevented or treated. |
priorityDate |
2017-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |